FDA approval for non-infectious uveitis drug

Article

Allergan has been given FDA approval for its drug Ozurdex (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation.

Allergan has been given FDA approval for its drug Ozurdex (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation.

The drug was assessed in a 26 week, multi-centre, double-masked, randomized clinical study in which 77 patients received Ozurdex 0.7mg and 76 patients received sham injections.

After a single injection of Ozurdex, the percentage of patients reaching a vitreous haze score of zero (being no inflammation) was statistically significantly greater for patients in the Ozurdex treated group versus sham at the week eight primary endpoint. In addition, the percentage of patients achieving a 3-line improvement in BCVA was 43 per cent in the Ozurdex treated group, versus 7 per cent for the sham group at week eight.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.